CUA Educational Content

Drug Access Listing: Advanced Prostate Cancer

With the expanded armamentarium of oral therapies for management of advanced prostate cancer, urology-oncology specialists have more options to consider for their patients. Access to these important therapies through provincial public funding or patient support programs is evolving and can be challenging for prescribers to uncover and navigate.

To assist physicians in identifying public and patient support program access mechanisms, the CUA has developed a drug listing of oral prostate cancer therapies and relevant outpatient injectables (e.g. bone health agents) with provincial funding criteria and support program details (e.g. criteria, contacts, weblinks) organized by province.